BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35411248)

  • 1. PIK-75 overcomes venetoclax resistance
    Huang S; Liu Y; Chen Z; Wang M; Jiang VC
    Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
    Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
    EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
    Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
    Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma.
    Granau AM; Andersen PA; Jakobsen T; Taouxi K; Dalila N; Mogensen JB; Kristensen LS; Grønbæk K; Dimopoulos K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.
    Li Y; Lee HH; Jiang VC; Che Y; McIntosh J; Jordan A; Vargas J; Zhang T; Yan F; Simmons ME; Wang W; Nie L; Yao Y; Jain P; Wang M; Liu Y
    Cell Death Dis; 2023 Nov; 14(11):714. PubMed ID: 37919300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
    Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
    Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Thus YJ; Eldering E; Kater AP; Spaargaren M
    Leukemia; 2022 Sep; 36(9):2165-2176. PubMed ID: 35725771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.
    Zhang Y; Lu P; Zhou Y; Zhang L
    PeerJ; 2021; 9():e12571. PubMed ID: 35003920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status.
    Dolnikova A; Kazantsev D; Klanova M; Pokorna E; Sovilj D; Kelemen CD; Tuskova L; Hoferkova E; Mraz M; Helman K; Curik N; Machova Polakova K; Anděra L; Trněný M; Klener P
    Blood Adv; 2024 May; ():. PubMed ID: 38713893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Guan J; Huang D; Yakimchuk K; Okret S
    Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
    Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
    Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein kinase C in mantle cell lymphoma.
    Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
    Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.